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1. Introduction 
The physiological post-synaptic receptor of acetyl- 
choline is nowadays a well identified protein which 
can be selectively abelled, purified and studied in its 
membrane environment [1-3].  However, progress 
in the understanding of the transient change of 
permeability riggered by acetylcholine brings upon 
the difficulty to correlate the actual binding of acetyl- 
choline to its receptor site and the subsequent opening 
of the associated ionophores in the time scale of 
synaptic transmission, i.e. in the millisecond range. 
Several fluorescent cholinergic ligands have already 
been used to study the binding properties of the 
nicotinic receptor protein from fish electric organ in 
its membrane-bound [4-6], and purified [7] forms 
and to monitor its conformational transitions [4,5,8]. 
These compounds behave in vivo on Electrophorus 
electroplaque orat the neuromuscular junction either 
as competitive antagonists [6,7] local anesthetics [8] 
or mixed effectors with both an agonistic haracter 
and a noncompetitive blocking activity [4,5]. It was 
therefore of importance to develop fluorescent 
*Recipient of a fellowship from the Deutsche Forschungs- 
gemeinschaft. 
ligands which, without ambiguity, would exhibit an 
agonistic haracter in vivo. 
A series of compounds has been synthetized 
which, like DNS-chol [9,4,5] possess a fluorescent 
dansyl residue and a quaternary nitrogen. In addition, 
hydrocarbon chains with varying lengths (1 to 5 
carbon atoms) have been inserted between the dansyl 
group and the acylcholine moiety. Those [ 1-(5- 
dimethylamino aphthalene)sulfonamido] n-alkanoic 
acid/3-(N-trimethylammonium bro ide)ethyl esters 
(CnDAChol) (see fig.3 for formula) show all the 
absorption and fluorescence properties of the dansyl 
chromophore. On the isolated electroplaque from 
Electrophorus, the first two members of the series 
(C1 and C2 DAChol) behave primarily as non compe- 
titive blocking agents. However the C3, C4 and Cs 
derivatives applied in bath cause a significant depolariza- 
tion of the electroplaque and both their potency and 
apparent affinity increase with the length of their 
hydrocarbon chain. Preliminary 1H n.m.r, experiments 
do not reveal any preferential conformation of the 
probe in solution which might explain the differences 
in pharmacological activity noticed among the various 
compounds synthesized. In vitro experiments carried 
out with the receptor-rich membrane fragments from 
T. marmorata nd Cs DAChol show that, within a 
wide range of concentrations, this fluorescent agonist 
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may be conveniently used to selectively label the 
cholinergic receptor site. 
2. Materials and methods 
After 24 h, the solution was evaporated to dryness in 
vacuo and the yellow oily residue purified by 
chromatography on a silicagel column with benzene- 
ether 50/50 as the elution agent (yield: 50-60%). 
2.1. Synthesis of dansyl-acylcholines." CnDAChol 
Glycine, ~3-alanine, 7,6 ,w-aminoacids, dansyl- 
chloride, bromoethanol, trimethylamine, dicyclo- 
hexylcarbodiimide (DCC) were from Fluka. All the 
N-carbobenzoxy-amino acids (Z-amino acids) were 
prepared by standard methods [10]. 
2.1.1. N-carbobenzoxyaminoacids/3-bromoethyl ester 
A solution of DCC (0.01 mol)in 30 ml of dry 
tetrahydrofuran was added dropwise at 0°C under 
nitrogen to a mixture of the appropriate Z-amino 
acid (0.01 tool),/3-bromoethanol (0.01 mol) and 2 ml 
of pyridine in 30 ml of tetrahydrofuran. The reaction 
mixture was stirred for 24 h at 20°C. The formed 
dicyclohexylurea w s filtered and the excess of DCC 
was precipitated by addition of 1 ml of acetic acid. 
The solution, evaporated to dryness in vacuo was 
dissolved in 50 ml of benzene and washed succes- 
sively with HC1 1 N, H20, NaHCO3, H20 and dried 
over Na2SO4. The filtrate was evaporated to dryness 
and gave a residual oil (yield 70-80%). The purity 
of the compounds obtained in this step was checked 
by thin layer chromatography on silicagel using 
benzene-ether 50/50 mixture and n.m.r, spectroscopy. 
2.1.2. Amino acid/3-bromoethyl ester hydrobromides 
The Z-amino acid/3-bromoethyl esters (8.10 -3 mol) 
were dissolved in glacial acetic acid (10 ml) and a 
stream of dry hydrogen bromide was bubbled through 
the solution for t 5 rain. The excess of rlBr was 
eliminated by a stream of dry nitrogen. The solution 
was evaporated to dryness and the syrup used without 
purification for the next step. 
2.1.3. (5-dimethylaminonaphthalene-1 sulfonyl) 
amino acid/3-bromoethyl ester 
Under nitrogen, amixture of dansyl chloride 
(6.2 10 -3 mol) and triethylamine (6.2.10 -3 mol) 
in 30 ml of dry dichloromethane was added slowly at 
0°C to a stirred solution of any of the above hydro- 
bromides (6.2.10 -3 mol) and triethylamine 
(6.2.10 -3 mol) in 30 ml of anhydrous methanol. 
2.1.4. [ 1-(5-dimethylaminonaphthalene) sulfonamido] 
n-alkanoic acid/3-(N-trimethylammonium 
bromide)ethyl esters (CnDAChol). 
An excess of a cold solution of trimethylamine in 
benzene (30%) was added to a solution of an above 
bromo ester (1.27.10 -3 mol) in 5 ml of dry acetone 
and the mixture was heated in a sealed tube at 70°C 
for 24 h. The crystalline hydrobromide which separat- 
ed was filtered and the solution evaporated in vacuo 
to give a precipitate. The solid was recrystallized 
from methanol-acetone 50/50 (yield 40-50%). 
All the intermediates and the expected CnDAChol 
derivatives give centesimal nalysis in accordance with 
theory and their structure was verified by n.m.r. 
The different steps of the synthesis of CnDAChol 





Z-NH(CH2)nCOOCH2CH2 Br > 
CH3COOH 
Br- H3÷N(CH2)nCOOCH2 CH2 Br 






DNS(CH2)n COOCH2 CH2N ÷ (CH3)3Br- 
n = 1 to 5; Z = C6HsCH2-O-CO- 
2.2. Electrophysiology 
The pharmacological activity of the CnDAChol 
was studied in vivo on the isolated electroplaque from 
Electrophorus electricus [ 11 ]. Given concentrations 
of ligand were applied in bath and membrane 
potentials recorded according to Higman et al. [12]. 
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2.3. Preparation of receptor-rich membrane fragments 
from Torpedo marmorata electric organ. 
The membrane fragments were purified by centri- 
fugation in sucrose gradients following the method of 
Cohen et al. [13] with minor modifications. The 
purified fragments were concentrated by centrifuga- 
tion and resuspended in a solution of 10 -4 M para- 
methyl sulfonyl fluoride (a protease inhibitor [14]) 
and 0.02% NaN3 in distilled water. 
The concentration f cholinergic receptor sites 
was estimated by the method of Weber and Changeux 
[15] following the binding of [aH]c~-toxin from 
Na/a nigrieollis. 
Proteins were assayed by the method of Lowry 
et al. [16]. The specific activity of the membrane 
preparations u ed ranged from 1100 to 1500 nmol 
of [all]a-toxin binding site per g of protein. 
2.4. [ 3 H] acetylcholine displacement experiment 
Membrane fragments (6.10 -a M [all]a-toxin 
binding sites, 54/ag protein per ml) in Torpedo 
physiological saline solution (250 mM NaC1, 5 mM 
KC1, 4 mM CaC12, 2 mM MgC12 and 5 mM sodium 
phosphate, ptI 7.0) were first incubated for 60 min 
with 5.10 -s M Tetram, an acetylcholinesterase. 
inhibitor [17]. Then tritiated acetylcholine bromide 
(250 Ci/mol, Amersham) was introduced to a final 
concentration f 6.10 -a M. This solution was 
divided into 2 ml fractions, to which given concentra- 
tions of Cs DAChol ranging from 0 to 5 10 -s M, 
were added. Membranes were pelleted by a 120 min 
20 000 rev/min centrifugation i  a JA21 rotor of a 
J21 Beckman centrifuge (~ 45 000 g). 400/al aliquots 
of the supernatants were counted with 3.5 ml Bray 
for 4 min. in the 3H-channel of an Intertechnique 
scintillation counter. Corresponding aliquots of the 
samples were taken before centrifugation a d counted 
as well. The radioactivity of the supernatants after 
centrifugation gave the concentrations of free acetyl- 
choline. The difference between the total radioactivity 
of the suspension and that of the supernatants, after 
centrifugation, was taken as estimates of acetyl- 
choline bound to the membrane fragments. No 
quenching effects due to varying concentrations of 
Cs DAChol were observed. 
2.5. Spectroscopic measurements 
The CnDAChol were dissolved in Torpedo 
physiological solution and the absorption and 
fluorescence spectra recorded respectively with an 
Unicam SP800 spectrophotometer anda Jobin-Yvon 
spectrofluorimeter. The PMR spectra were recorded 
in DMSO d 6 and D20 buffer on a Bruker WH 90 
spectrometer in the Fourier transform mode, at a 
probe temperature of 30 -+ 1 °C, with tetramethylsilane 
(TMS) as external reference. 
The interaction of the CnDAChol with Torpedo 
membrane fragments was followed in Torpedo 
physiological saline solution with a FICA differential 
recording spectrofluorimeter. The quartz fluorescence 
cells containing the suspension supplemented with 
5-10 -s M Tetram were thermostated at 20°C during 
the experiment. 
3. Results 
3.1. Spectral properties of CnDA Chol in aqueous 
solution 
The absorption and fluorescence emission spectra 
of all the CnDAChol compounds studied appear 
identical (fig.l). The absorption spectra show the 
same absorption maxima t 216,246 and 328 rim. 
Upon illumination at 328 nm, maximal fluorescence 
emission is observed at 560 nm. In agreement 
with previous findings [4-6] ,  the spectral charac- 
teristics of the fluorescence spectrum change with 
solvent polarity: for instance transfer from water to 
ethanol causes an approx. 100 fold increase in 
maximal fluorescence intensity accompanied by an 
approx. 50 nm shift to the blue; also a shoulder 
appears around 450 nm. 
3.2.1H n. m r. spectroscopy of CnDA Chol 
The n.m.r, spectrum of Cs DAChol is shown in 
fig.2. No significant difference was noticed between 
the CnDAChol compounds studied in DMSO d6 and 
D~O buffer pH 7.0 at the same concentration. Only 
a slight variation of the CnDAChol spectrum with 
concentration was observed indicating little, if any, 
tendency to intermolecular interactions in aqueous 
solution [18]. Moreover, at low concentrations of 
the compound (5 X 10 -4 M), the chemical shift of 
the trimethylammonium group does not change when 
the length of the chain increases. This indicates that, 
despite differences in length, the several CnDAChol 
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Fig.l. Spectral properties of CsDAChol. ( -  - - )  Absorption spectrum of 4.10 -s M CsDAChol in Torlgedo physiological 
solution, e~ 6 = 3.55-104, e24 e = 1.55"104, e~28 = 0.55"104 M-~ cm -1 . (--  ) Fluorescence spectrum of I0- s M CsDAChol in 
Torpedo physiological solution (hex = 328 nm). (• - ~) Fluorescence spectrum of 10 -7 M CsDAChol in ethanol (hex = 328 nm). 
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Fig.2. t H n.m.r, spectrum of 10-2 M C s DAChol in a Torpedo physiological solution made in D 20.  
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compounds exhibit similar conformations. In particular, 
they do not show any tendency to intramolecular 
folding upon the aromatic moiety when the number 
of carbon atoms in the intermediary segment 
increases. 
3.3. Pharmacological ctivity in vivo of CnDAChol on 
Electrophorus electricus electroplaque 
Bath application of C1 or C2 DAChol, at con- 
centrations ranging from 10 -7 to 10 -4 M does not 
cause any significant change of membrane potential. 
However, both of them block reversibly the response 
to 3 × 10 -s M carbamylcholine in a non-competitive 
manner. On the other hand, C3, C4 or Cs DAChol 
behave, at low concentrations, as agonists (fig.3). 
The amplitude of the maximal depolarization recorded 
increases with n and reaches 15 mV (the third of the 
maximal response to carbamylcholine) for n = 5 
and the apparent dissociation constant (the concentra- 
tion of effector giving half of the maximal response) 
decreases when n increases. For instance, gap p = 
2.5 X 10 -6 M and 7 × l0 -7 M for C4 and Cs DAChol 
respectively and with all of them, the dose-response 
curve has a bell shape: at high concentrations of the 
compounds, the amplitude of the response decreases 
and becomes negligible. In this range of concentration, 
however, the CnDAChol block reversibly the response 
to carbamylcholine and behave as non-competitive 
antagonists. 
Since Cs-DAChol turned out to be the most potent 
agonist, it was most extensively studied in the follow- 
ing biochemical experiments. 
3.4. Effect of CsDAChol on the binding in vitro of 
[ 3 H] acetylcholine to Torpedo receptor-rich 
membrane fragments. 
The binding of [3H]acetylcholine was followed by 
centrifugation (see Materials and methods) under 
conditions where acetylcholine binds almost exclusively 
to the cholinergic receptor site (complete displacement 
by N. nigricollis a-toxin). Fig.4 shows that, when 
approx. 65% of the receptor sites were occupied by 
acetylcholine, CsDAChol displaces quantitatively 
acetylcholine bound to the membrane fragments. At 
CH 3 CH 3 
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Fig.3. Pharmacological response of the isolated electroplaque from Electrophorus electricus to CnDAChol. E = membrane 
potential; Eo = resting potential ( -  80 mV); the amplitude of the maximal response to carbamylcholine (E - Eo) was approx. 
50 mV. 
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Fig.4. Binding of CsDAChol to Torpedo receptor-rich 
membrane fragments as followed either by displacement 
of [3H]acetylcholine orby fluorescence spectroscopy. 
(o - o) Displacement of [3H]acetylcholine (see Materials 
and methods). (r - .) Fluorescence experiment. The sample 
and reference cells contained 2.5 ml of Torpedo physiological 
solution supplemented with membrane fragments (2 × 10 -7 M 
in N. nigricollis a-toxin sites, 130 ~g protein per ml) and 
10 -4 M Tetram. A saturating concentration f acetylcholine 
bromide (10 -4 M) was added to the reference cell; the 
indicated concentration of C.~ DAChol was then introduced 
in both cells, hex = 290 nm (energy transfer), hem = 557 nm 
(maximum emission wavelength). 
saturating levels of CsDAChol negligible amounts of 
[3H] acetylcholine remain associated to the membrane 
fragment. Assuming a mutually exclusive binding of 
CsDAChol and acetylcholine and equal numbers of 
acetylcholine and [3H]a-toxin binding sites, one 
estimates from the displacement curve, a dissociation 
constant of 4.5 X 10 -8 M for CsDAChol (and of 
1.2 × 10 -8 M [5] for acetylcholine). 
3.5. The interaction in vitro of CsDAChol with 
Torpedo receptor-rich membrane fragments 
followed by fluorescence spectroscopy 
In a first series of experiments he fluorescence 
emission of CsDAChol was followed by direct excita- 
tion in one of the bands where it maximally absorbs 
(kex = 325 nm). Addition of membrane fragments 
(2 × 10 -7 M final concentration i [3H]a-toxin sites) 
to a 1/aM solution of Cs DAChol in Torpedo physiological 
solution causes a significant increase in fluorescence 
intensity between 400 and 560 nm (about 30% at 
500 nm, the intrinsic protein fluorescence being sub- 
tracted). The subsequent addition ofN. nigricollis 
a-toxin or carbamylcholine to the mixture further 
modifies the fluorescence spectrum: at wavelengths 
larger than 490 nm, as expected, the signal intensity 
decreases (by about 20% at 560 nm). CsDAChol, 
therefore, interacts with the membrane fragments at 
a site sensitive to specific nicotinic ligands. Under 
these conditions a significant enhancement of the 
fluorescence at wavelengths shorter than 490 nm 
was observed (about 80% at 460 nm). 
In order to record fluorescence signals more 
exclusively related to CsDAChol bound to the mem- 
brane fragments, excitation by energy transfer from 
membrane proteins (kex = 290 nm) was used instead 
of direct excitation. 
Under excitation at 290 nm the emission of 
Cs DAChol free in solution is minimum. However, an 
overlap between protein fluorescence emission and 
CsDAChol excitation spectra indeed exists. The 
measurements were therefore performed by differential 
spectroscopy under the following conditions: both 
reference and sample cells contained the suspension of 
membrane fragments (2 × 10 -7 M in [3H]a-toxin sites) 
in physiological saline solution and CsDAChol was 
added to the sample cell. Fig.5 shows the emission 
spectrum recorded in the presence of 1/aM CsDAChol. 
A comparison with the emission spectrum of free 
CsDAChol reveals that the wavelength of the 
CsDAChol emission maximum is shifted by about 
10 nm to the blue. In order to test the specificity of 
the fluorescence emission signal, 8/aM a-toxin from 
N. nigricollis was added to both cells: a marked 
decrease of fluorescence intensity took place without 
significant change of the wavelength of maximal 
emission. The same observation was obtained with 
another typical nicotinic antagonist: flaxedil. On the 
other hand, when an agonist, such as carbamylcholine, 
was used instead of an antagonist, he fluorescence 
emission decreased as well but a marked shift to the 
blue, of about 55 nm, was noticed. This observation 
confirms and further amplifies previous findings 
with DNS-chol and the same membrane fragments [4,5] 
As already suggested in the case of DNS-chol 
[4,5] the simplest interpretation of the data is that 
Cs DAChol binds to, at least, two categories of sites: 
the cholinergic receptor site and secondary sites, 
distinct from the previous ones, where Cs DAChol 
fluorescence emission differs when the receptor site 
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Fig.5. Differential f uorescence emission spectra of C~DAChol in the presence of Torpedo receptor-rich membrane fragments. 
Effect of cholinergic ligands. Membrane fragments (2.10 -7 MN. nigricollis t~-toxin binding sites, 180 pg protein per ml) in 
Torpedo physiological solution were present in sample and reference cells (base line). CsDAChol was added to sample cell and 
spectrum recorded. In (A), the indicated concentration of carbamylcholine and then of prilocaine was introduced in both cells; 
for (B), a-toxin followed by prilocaine, to both ceils. The arrows indicate the emission maxima. 
is occupied by an agonist or an antagonist [4,5]. To 
test the hypothesis [5] that these secondary sites are, 
in some manner, related to the local anesthetic 
binding site, prilocaine (1-11 mM) was added after 
the suspension was supplemented with carbamyl- 
choline or a-toxin. A further decrease of fluorescence 
intensity took place and, again, as found with DNS-chol 
[5] prilocaine reversed the blue shift observed in the 
presence of agonists. 
Qualitatively, CsDAChol behaves in a manner 
similar to DNS-chol. Important quantitative 
differences, however, were noticed. First, the blue 
shift caused by the agonists is significantly larger 
than that found with DNS-chol. Moreover, conditions 
can be found under which the fluorescence signal 
associated with the binding of CsDAChol to the 
receptor site can be separated almost completely 
from that associated with the secondary sites and free 
CsDAChoI: measurements of the decrease of 
fluorescence intensity which accompanies the dis- 
placement of CsDAChol from the cholinergic receptor 
site by either a-toxin or agonists indicate that at low 
concentrations (< 6.10-7 M) of C5 DAChol the 
fluorescence signal which is not associated with ACh 
binding sites represents less than 15% of the total 
signal. 
Moreover the incidence, of these remaining 15% 
can be diminished using the following experimental 
set up. Both sample and reference cells contained 
membrane fragments plus CsDAChol and an excess 
of acetylcholine was added to the reference cell. 
The difference signal was then studied as a function 
of Cs DAChol concentration (fig.4). Assuming that 
the fluorescence quantum yield of CsDAChol bound 
to the ACh receptor site is independant of the 
average occupancy of the sites and that the number 
of a-toxin and ACh binding sites are equal, one can 
estimate a dissociation constant for CsDAChol of 
4.5-10 -a M. 
Interestingly, this value is very close to that 
found by direct displacement of [3H]acetylcholine 
bound at equilibrium to the membrane-bound 
receptor. 
At concentrations of CsDAChol larger than 10 -6 M, 
the acetylcholine binding sites are already saturated 
and the contribution to the fluorescence signal from 
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CsDAChol bound to the secondary sites and from 
free CsDAChol becomes ignificant. Yet, for technical 
reasons the dissociation constants of CsDAChol from 
these secundary sites have not been measured. 
4. Conclusion 
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We thank A. Sobel, M. Weber and H. Buc for 
helpfull advices and comments. We would like to 
specially acknowledge Simone Mougeon for her skill 
and initiative in performing the electrophysiological 
experiments. 
Electrophysiological and biochemical observations 
confirm that the CnDAChol compounds, like DNS-chol, 
behave both as agonistic and non-competitive blocking 
agents. However, increasing the length of the chain 
between the choline moiety and the dansyl residue 
markedly enhances the agonistic haracter of the 
molecule as manifested by both the amplitude of the 
maximal response and the apparent dissociation 
constant. Preliminary 1H n.m.r, experiments, however, 
do not reveal differences of conformation which might 
simply explain the phenomenon. 
Fluorescence studies done by energy transfer with 
the Cs member of the series show that this compound, 
like DNS-chol, binds to Torpedo membrane fragments 
at the level of two distinct population of sites: the 
acetylcholine receptor site and secondary sites related 
to the local anesthetic binding site. However, at 
variance with what was found with DNS-chol and 
probably because of the preferential and high affinity 
of CsDAChol to the cholinergic receptor site, con- 
ditions can be defined where the fluorescence signal 
reflects, almost exclusively, the occupancy of the 
receptor site by CsDAChol. This compound may 
therefore become an useful probe to follow, by rapid 
kinetic techniques, the binding of an agonist o the 
membrane bound cholinergic receptor protein and to 
analyse the conformational changes it triggers. 
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